Effects Of Antidepressants On Sexual Functioning In Adults
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00051272|
Recruitment Status : Completed
First Posted : January 8, 2003
Last Update Posted : March 29, 2011
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder (MDD)||Drug: Extended-release Bupropion Hydrochloride||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||425 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Multicenter, Double-blind Randomized Placebo-controlled Comparison of the Effects on Sexual Functioning of Extended-release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients With Moderate to Severe Major Depression Over an Eight-Week Treatment Period|
|Study Start Date :||January 2003|
|Actual Primary Completion Date :||June 2004|
|Actual Study Completion Date :||June 2004|
- Percent of subjects with orgasm dysfunction. Change from baseline in HAMD-17 total score.
- Percent of subjects in remission, HAMD-17. Changes in Sexual functioning Questionnaire. CGI-I and CGI-S. Percent of responders, HAMD-17.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00051272
Show 24 Study Locations
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|